GSK Pulls EU Filing For Jesduvroq In CKD Anemia After Label Narrowed

GSK’s Jesduvroq was set for imminent EU approval to treat anemia in patients with chronic kidney disease receiving dialysis, but the firm has withdrawn its marketing authorization application after the EMA recommended excluding non-dialysis patients from the label.

Withdrawn Stamp
• Source: Shutterstock

Last month, the European Medicines Agency’s scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), issued a positive recommendation for the marketing authorization of GSK plc’s oral drug candidate Jesduvroq (daprodustat) to treat adults with symptomatic anemia with chronic kidney disease (CKD) on dialysis. (Also see "EU CHMP Opinions And MAA Updates" - Pink Sheet, 26 June, 2023.).

Yet before Jesduvroq was granted approval from the European Commission, which usually occurs within 67 days of the CHMP adopting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Swissmedic Appoints Trivigno As New Agency Head From 2026

 

Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

Denmark Introduces First Confidential Pricing Framework For Primary Care Medicines

 

Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

More from Geography

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By 

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.